| Autor: |
James Witek, Goedele De Smedt, Veerle Vyncke, Richard M. W. Hoetelmans, Thomas N. Kakuda, Kurt Spittaels, Monika Schöller-Gyüre, Sophie H. Akuma |
| Rok vydání: |
2013 |
| Předmět: |
|
| Zdroj: |
The Journal of Clinical Pharmacology. 53:202-210 |
| ISSN: |
0091-2700 |
| Popis: |
Background A previous study investigating coadministration of etravirine, a nonnucleoside reverse transcriptase inhibitor, and lopinavir/ritonavir soft-gel formulation resulted in nonclinically relevant changes in etravirine and lopinavir exposure. The current study evaluated the pharmacokinetic interaction between etravirine and the lopinavir/ritonavir melt extrusion formulation. Method Sixteen human immunodeficiency virus (HIV)-negative volunteers were randomized to either treatment sequence A/B or B/A, with 14 days— washout between treatments (treatment A: etravirine 200 mg bid for 8 days; treatment B: lopinavir/ritonavir 400/100 mg bid for 16 days with etravirine 200 mg bid on days 9-16). Steady-state pharmacokinetics were assessed for all antiretrovirals alone and coadministered; pharmacokinetic parameters were obtained by noncompartmental analysis. Safety and tolerability were assessed. Results Coadministration of etravirine and lopinavir/ritonavir resulted in a 35% decrease in etravirine exposure. Smaller decreases ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text